Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Factor VIII Fc Fusion Protein On-demand and Prophylaxis in Severe Hemophilia A
CTR20254859Phase 3Active
- Sponsor
- Chengdu Rongsheng Pharmaceutical
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Factor VIII in hemophilia A, sponsored by Chengdu Rongsheng Pharmaceutical. Started Dec 2025; status: active.
02
Drugs
Factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20254859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254859.